These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3242648)

  • 1. Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors.
    Meyer JS; Province M
    Breast Cancer Res Treat; 1988 Oct; 12(2):191-204. PubMed ID: 3242648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast carcinoma cell kinetics, morphology, stage, and host characteristics. A thymidine labeling study.
    Meyer JS; Prey MU; Babcock DS; McDivitt RW
    Lab Invest; 1986 Jan; 54(1):41-51. PubMed ID: 3941541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of early course of breast carcinoma by thymidine labeling.
    Meyer JS; Friedman E; McCrate MM; Bauer WC
    Cancer; 1983 May; 51(10):1879-86. PubMed ID: 6831353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.
    Meyer JS; Province MA
    Cancer; 1994 Oct; 74(8):2287-99. PubMed ID: 7922981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy.
    Meyer JS; Wittliff JL
    Int J Cancer; 1991 Jan; 47(2):213-20. PubMed ID: 1988366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical breast carcinoma cell kinetics: review and update.
    Meyer JS; McDivitt RW; Stone KR; Prey MU; Bauer WC
    Breast Cancer Res Treat; 1984; 4(2):79-88. PubMed ID: 6378283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis.
    Rudas M; Gnant MF; Mittlböck M; Neumayer R; Kummer A; Jakesz R; Reiner G; Reiner A
    Breast Cancer Res Treat; 1994; 32(2):165-75. PubMed ID: 7865846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid receptors and prognosis in operable (stage I and II) breast cancer.
    Stewart JF; Rubens RD; Millis RR; King RJ; Hayward JL
    Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1381-7. PubMed ID: 6315442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma.
    Meyer JS
    NCI Monogr; 1986; (1):25-8. PubMed ID: 3774013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.
    Vollenweider-Zerargui L; Barrelet L; Wong Y; Lemarchand-Béraud T; Gómez F
    Cancer; 1986 Mar; 57(6):1171-80. PubMed ID: 3943040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell kinetic analysis of human breast carcinomas.
    Meyer JS
    Monogr Pathol; 1984; (25):45-58. PubMed ID: 6377051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index.
    Silvestrini R; Daidone MG; Luisi A; Mastore M; Leutner M; Salvadori B
    Int J Cancer; 1997 Feb; 74(1):122-7. PubMed ID: 9036880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.
    Meyer JS; Rao BR; Stevens SC; White WL
    Cancer; 1977 Nov; 40(5):2290-8. PubMed ID: 922670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome.
    Ozmen V; Cabioglu N; Dolay K; Bilir A; Kecer M; Aydiner A; Muslumanoglu M; Igci A; Bozfakioglu Y; Dagoglu T
    Breast Cancer Res Treat; 2001 Jul; 68(2):147-57. PubMed ID: 11688518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology and behavior of small breast carcinomas.
    Meyer JS; Fahrner M; Daniel FC
    Semin Diagn Pathol; 1999 Aug; 16(3):257-68. PubMed ID: 10490202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
    Alexieva-Figusch J; Van Putten WL; Blankenstein MA; Blonk-Van Der Wijst J; Klijn JG
    Cancer; 1988 Feb; 61(4):758-68. PubMed ID: 3338038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidine labeling index: prognostic role in breast cancer.
    Bilir A; Ozmen V; Kecer M; Eralp Y; Cabioglu N; Ahishali B; Camlica H; Aydiner A
    Am J Clin Oncol; 2004 Aug; 27(4):400-6. PubMed ID: 15289735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
    Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
    Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell proliferation of the primary tumor predicts ipsilateral axillary node disease in elderly breast cancer patients.
    Silvestrini R; Martelli G; Miceli R; Agresti R; Veneroni S; Daidone MG
    Int J Biol Markers; 2013 Apr; 28(1):24-31. PubMed ID: 23558937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the Tritiated Thymidine Labeling Index in breast cancers.
    Araki K; Kimura M; Sakamoto K; Nishimura R; Akagi M
    Jpn J Surg; 1985 Mar; 15(2):144-9. PubMed ID: 4010096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.